Windgap Medical, a Watertown MA-based provider of a pharmaceutical and drug delivery platform, raised $39M in Series B-1 funding.
The round was led by Taiwania Capital with participation from Shepherd Kaplan Krochuk, Molex Ventures and Cobro Ventures.
The company intends to use the funds to energize the ongoing epinephrine commercialization process and grow the pipeline of additional products utilizing the autoinjector technology.
Led by Christopher Stepanian, CEO, and Brent Buchine PhD, Chief Technology Officer, Windgap is a pharmaceutical company focused on developing patient solutions with its patented wet/dry drug delivery platforms. The first product to use this platform will be epinephrine for the treatment of anaphylaxis. Other pipeline products include a novel emergency treatment for cyanide poisoning that is sponsored by the National Institutes of Health through a multi-year CounterACT grant, led by the University of Minnesota Twin Cities.
Windgap’s products have not been reviewed by the FDA, but the company intends to seek approval, first, for its epinephrine product for anaphylaxis.
FinSMEs
21/01/2022